Tests start on the first 50 volunteers for the universal formula to mRna (ANSA). The study involves the enrollment of 50 volunteers between 18 and 49 years old.
The new vaccine aims to boost immunity against influenza by using a portion of a protein characteristic of influenza viruses: hemagglutinin. This protein has two portions: one that evolves very quickly and one that is more stable and has very similar characteristics in different influenza viruses. This could make it able to offer lasting protection against multiple influenza virus.